Navigation Links
WuXi PharmaTech Announces First-Quarter 2010 Results
Date:5/11/2010

ness. Gross margin from Laboratory Services improved year over year to 41.4% from 40.2% due to improved profitability of newer China-based downstream laboratory services and of U.S.-based laboratory services, partially offset by increased expenses related to the ramp-up of the Suzhou toxicology facility. Gross margin declined year over year in Manufacturing Services to 19.9% from 22.7%, primarily due to project mix and the beginning of depreciation of the large-scale manufacturing facility.

First-quarter 2010 GAAP operating income grew 70% to $17.4 million due to the 30% increase in gross profit and essentially flat operating expenses driven by cost control.

First-quarter 2010 GAAP net income increased 32% to $15.5 million due to the 70% increase in operating income, offset by higher taxes and an unfavorable change in other income (expenses) net. Other income (expenses) net in first-quarter 2010 included foreign-exchange losses of $0.4 million, compared to $3.3 million of foreign-exchange gains in first-quarter 2009.

First-quarter 2010 GAAP diluted earnings per ADS increased 30% to 21 cents, mainly due to the 32% increase in net income, offset by higher share count due to stock-option activity.

Non-GAAP Results

Non-GAAP financial results excluded the impact of share-based compensation expenses and amortization of acquired intangible assets and the associated deferred tax impact.

First-quarter 2010 non-GAAP gross profit increased 30% year over year to $32.1 million, mainly due to revenue growth. First-quarter 2010 non-GAAP gross margin dec
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. WuXi PharmaTech Schedules First-Quarter 2010 Earnings Release
2. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
3. WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai
4. WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release
5. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
6. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
7. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
8. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
9. Jazz Pharmaceuticals Announces Public Offering of Common Stock
10. Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-2104R MRI Imaging Agent
11. Somanetics Corporation Announces 24 Clinical Abstracts on INVOS System Presented at Annual Pediatric Academic Societies National Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Biopharmaceutical Industry Leads Manufacturing Sector in R&D Spending ... as the country,s manufacturing leader in innovation and economic ... to the  analysis , the industry had the highest ... accounting for 27 percent of average annual R&D spending ... on Medicare Part D - Medicare Part D ...
(Date:3/27/2015)... 2015 The Temple Health & Bioscience District (THBD) ... building at 1802 South First St. in the Temple Medical ... City of Temple to receive funding ... Central Texas Veterans Health Care System, the new facility will ... stage biotechnology and life science companies. ...
(Date:3/27/2015)... A new report from Kalorama Information says that other countries ... Chile , Colombia and ... The healthcare research firm said that while Brazil ... American continent with a population of over 200 million people ... country,s regional economic clout does not necessarily ensure its status ...
Breaking Medicine Technology:Week in Review: The Latest from PhRMA 2Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4
... May 2, 2012 Zogenix, Inc. (NASDAQ: ... for the treatment of central nervous system disorders and ... New Drug Application (NDA) to the U.S. Food and ... Zogenix,s lead investigational product candidate for the treatment of ...
... 2012 Oxford BioTherapeutics (OBT) today announces ... Officer (COO) of the OBT group. In this position ... operations based in Basel, Switzerland.  The establishment of a ... global expansion as it progresses its most advanced therapeutic ...
Cached Medicine Technology:Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 2Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 3Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 4Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 5Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 6Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland 2Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland 3
(Date:3/28/2015)... 2015 Could genetic code determine someone’s ... study by researchers at the Harvard T.H. Chan ... support of the Coffee and Caffeine Genetics Consortium and ... past fall, the study—one of several recent HSPH investigations ... from more than 120,000 regular coffee drinkers of European ...
(Date:3/28/2015)... 2015 Thousands of transvaginal mesh ... C.R. Bard, Inc. continue to move forward in ... Southern District of West Virginia, where Bernstein Liebhard ... Plaintiffs’ Steering Committee. According to an Order ... defendants named in those lawsuits leave to amend ...
(Date:3/28/2015)... York, NY (PRWEB) March 28, 2015 ... highlighted a problem which could prove critical to organizations ... system testing, a critical aspect of data security, is ... card industry data security report, every major category out ... scanning and penetration testing. “With all the craziness that ...
(Date:3/28/2015)... 2015 How best to treat and ... in orthopaedic medicine. While diagnostic hip injections are commonly ... pain etiology, research presented today at the American Orthopaedic ... suggests that pain relief from this diagnostic injection may ... , “Our study looked to assess if the amount ...
(Date:3/28/2015)... March 28, 2015 Andrew Hawley of Vintage ... Who psychedelic concert posters. The Who and the Doors played ... August 2, 1968. According to Hawley, “The Who toured the ... halls and college campuses. Perhaps the most famous Who poster ... Morrison and the Doors on August 2, 1968 at the ...
Breaking Medicine News(10 mins):Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2
... Age should not be a factor in determining ... shown that older heart transplant patients do just as ... evaluated all 275 adult patients who received a heart ... and 2000. The patients' mortality and morbidity rates were ...
... and people without liver cancer found that diabetics are stand ... the general population.// ,After taking other factors into account, ... researchers found diabetes nearly tripled the risk of liver cancer. ... for liver cancer, may be boosting the risk even further. ...
... cause skin cancer – melanoma ,however researchers as the number ... number of patients surviving the disease. // Two new studies ... kinds of cancer. In a study conducted by researchers on ... it was discovered that melanoma patients with higher levels of ...
... The most deadly form of skin cancer , advanced ... with tumor proteins, say researchers according to a recent ... with tumor antigens (called MAGE-3) might have on patients’ ... was found that injecting patients with the tumor antigens ...
... a recent study researchers focused on the use ... their impact on cholesterol and C-reactive protein levels. ... the liver that predicts inflammation in the arteries. ... important key to determining cardiovascular risk.,Researchers focused on ...
... the heart's own can, such as raising the heart rate ... a hill but researchers say a pacemaker created by // ... have shown that genetically engineered heart cells from human embryonic ... according to a new study. Researchers injected clusters of human ...
Cached Medicine News:
... Plus Retics is a 5-part differential control ... the Abbott CELL-DYN 3200, 3500, 3700 and ... contains nucleated red blood cells that can ... 4000. The assay contains automated and manual ...
... Sickle-Chex is a positive and negative whole ... of Hemoglobin S in solubility tests and ... SICKLEDEX and other manufacturers' solubility kits. ... squeeze dropper vial. The vial dispenses an ...
... blood hematology control manufactured specifically for the ... the Coulter AcT5diff instruments. The composition of ... differential, positioning the populations within the limitations ... product offers 105-day closed-vial stability and 14-day ...
... STaK-Chex, a whole blood assayed hematology ... five-part white cell differential available with the ... unique product has 14-day open-vial stability, 105-day ... normal and high levels. The 4.0ml pierceable ...
Medicine Products: